Proteomic Profiling of Cerebrospinal Fluid and Serum in Schizophrenia Using a Label-free Mass Spectrometric Approach
In this study, we employed a label-free mass spectrometry based approach to determine proteomic profiles from CSF and sera samples from first-onset, drug-naïve paranoid schizophrenia patients and healthy controls. Seventy seven proteins were detected with high confidence, in at least three of the samples. Of these, seven proteins were newly identified in CSF. Partial least squares discriminant analysis showed a significant separation of first-onset, drug-naive schizophrenia patients away from healthy controls in this study. From this study a number of putative biomarker proteins, some associated with other neurological disorders are undergoing further validation.